Nolvadex (Tamoxifen)

Tamoxifen, the active ingredient in Nolvadex, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is employed in the endocrine therapy of estrogen receptor‑positive breast cancer, both in early‑stage adjuvant settings and in metastatic disease.

GNH USA supplies Nolvadex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing consistent quality assurance and full regulatory compliance for global distribution. The product meets EU pharmacopeial standards and is manufactured under GMP conditions.

Tamoxifen is used in endocrine therapy for estrogen‑dependent breast cancer and related conditions. - Estrogen receptor‑positive early breast cancer: Reduces risk of recurrence after surgery and adjuvant therapy, supporting long‑term disease‑free survival. - Metastatic breast cancer: Delays disease progression and may improve overall survival in patients with hormone‑responsive metastatic lesions. - Prevention of breast cancer recurrence: Decreases likelihood of tumor return following primary treatment, contributing to extended remission periods. - High‑risk women for breast cancer: Lowers incidence of first invasive breast cancer in selected high‑risk populations, such as those with a strong family history.

Tamoxifen may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hot flashes: Transient intense warmth, often with sweating and flushing, usually occurring at night. - Nausea: Mild to moderate stomach upset that may improve with food or anti‑emetics. - Fatigue: Persistent tiredness affecting daily activities and not relieved by rest. - Vaginal discharge or dryness: Hormonal changes causing either increased discharge or dryness, leading to discomfort.

Serious or Rare Side Effects: - Thromboembolic events: Deep vein thrombosis or pulmonary embolism, presenting with leg pain, swelling, or sudden shortness of breath. - Endometrial cancer: Uncommon malignant growth of the uterine lining, may cause abnormal uterine bleeding. - Severe liver dysfunction: Jaundice, markedly elevated liver enzymes, or hepatic failure requiring medical attention.

When prescribing tamoxifen, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy risk: Category D; avoid use during pregnancy due to potential fetal harm. - Thromboembolic risk: Assess patient history of clotting disorders before initiating therapy. - Endometrial monitoring: Perform regular gynecologic examinations for signs of uterine changes. - Liver function: Monitor hepatic enzymes periodically, especially in patients with pre‑existing liver disease. - Drug interactions: Review concomitant medications for CYP2D6 inhibitors that may reduce efficacy. - Store at ambient temperature: Keep tablets below 25°C in the original container, protected from moisture and direct light.

Tamoxifen can interact with several medicines that affect its metabolism or increase the risk of adverse events.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): Reduce conversion to active metabolites, diminishing therapeutic effect. - Anticoagulants (e.g., warfarin): Heighten bleeding risk; close monitoring required. - Hormonal contraceptives: May decrease tamoxifen efficacy and alter contraceptive reliability.

Moderate Interactions (Monitor Closely): - SSRIs with moderate CYP2D6 inhibition (e.g., sertraline): May modestly affect tamoxifen activity. - Aromatase inhibitors: Concurrent use can lead to antagonistic hormonal effects. - CYP3A4 inducers (e.g., rifampin): May lower tamoxifen plasma levels.